Cerus Corporation Announces Second Quarter 2024 Financial Results and Increases Full-Year 2024 Product Revenue Guidance Range
Cerus (Nasdaq: CERS) announced strong Q2 2024 financial results and increased its full-year 2024 product revenue guidance. Key highlights include:
- Q2 2024 product revenue: $45.1 million, up 16% year-over-year
- H1 2024 product revenue: $83.4 million, up 20% year-over-year
- Full-year 2024 product revenue guidance raised to $175-178 million
- Q2 2024 GAAP net loss narrowed to $5.8 million
- Q2 2024 non-GAAP adjusted EBITDA: $0.8 million
- Positive operating cash flows of $2.4 million year-to-date
- Cash and investments: $71.2 million as of June 30, 2024
The company reported strong growth in its platelets business, particularly in North America, and accelerating adoption of INTERCEPT Fibrinogen Complex (IFC). Cerus remains committed to achieving adjusted EBITDA breakeven for the full-year 2024.
Cerus (Nasdaq: CERS) ha annunciato risultati finanziari forti per il secondo trimestre del 2024 e ha aumentato le previsioni di fatturato per l'intero anno 2024. I punti salienti includono:
- Fatturato da prodotti nel secondo trimestre 2024: 45,1 milioni di dollari, in aumento del 16% rispetto all'anno precedente
- Fatturato da prodotti nel primo semestre 2024: 83,4 milioni di dollari, in aumento del 20% rispetto all'anno precedente
- Previsioni di fatturato da prodotti per l'intero anno 2024 aumentate a 175-178 milioni di dollari
- Perdita netta GAAP nel secondo trimestre 2024 ridotta a 5,8 milioni di dollari
- EBITDA rettificato non-GAAP per il secondo trimestre 2024: 0,8 milioni di dollari
- Flussi di cassa operativi positivi di 2,4 milioni di dollari da inizio anno
- Liquidità e investimenti: 71,2 milioni di dollari al 30 giugno 2024
L'azienda ha riportato una forte crescita nel suo business delle piastrine, in particolare in Nord America, e una crescente adozione dell'INTERCEPT Fibrinogen Complex (IFC). Cerus rimane impegnata a raggiungere il pareggio di EBITDA rettificato per l'intero anno 2024.
Cerus (Nasdaq: CERS) anunció resultados financieros sólidos para el segundo trimestre de 2024 y elevó su guía de ingresos por productos para todo el año 2024. Los aspectos más destacados incluyen:
- Ingresos por productos en el segundo trimestre de 2024: 45,1 millones de dólares, un aumento del 16% en comparación con el año anterior
- Ingresos por productos en el primer semestre de 2024: 83,4 millones de dólares, un aumento del 20% en comparación con el año anterior
- Guía de ingresos por productos para todo el año 2024 aumentada a 175-178 millones de dólares
- Pérdida neta GAAP en el segundo trimestre de 2024 reducida a 5,8 millones de dólares
- EBITDA ajustado no-GAAP en el segundo trimestre de 2024: 0,8 millones de dólares
- Flujos de efectivo operativos positivos de 2,4 millones de dólares hasta la fecha
- Efectivo e inversiones: 71,2 millones de dólares al 30 de junio de 2024
La empresa reportó un sólido crecimiento en su negocio de plaquetas, particularmente en América del Norte, y una adopción acelerada del INTERCEPT Fibrinogen Complex (IFC). Cerus sigue comprometida a lograr el equilibrio de EBITDA ajustado para todo el año 2024.
세러스(Cerus, Nasdaq: CERS)는 2024년 2분기 강력한 재무 실적을 발표하고 2024년 전체 연도 제품 수익 가이드를 상향 조정했습니다. 주요 하이라이트는 다음과 같습니다:
- 2024년 2분기 제품 수익: 4,510만 달러, 전년 대비 16% 증가
- 2024년 상반기 제품 수익: 8,340만 달러, 전년 대비 20% 증가
- 2024년 전체 연도 제품 수익 가이드를 1억 7,500만-1억 7,800만 달러로 상향 조정
- 2024년 2분기 GAAP 기준 순손실 580만 달러로 축소
- 2024년 2분기 비GAAP 조정 EBITDA: 80만 달러
- 현재까지 긍정적인 운영 현금 흐름 240만 달러
- 2024년 6월 30일 기준 현금 및 투자: 7,120만 달러
회사는 북미에서 특히 혈소판 사업에서 강력한 성장을 보고했으며, INTERCEPT 피브리노겐 복합체(IFC)의 채택이 가속화되고 있습니다. 세러스는 2024년 전체 연도 조정 EBITDA 손익 분기점을 달성하기 위해 최선을 다하고 있습니다.
Cerus (Nasdaq: CERS) a annoncé de solides résultats financiers pour le deuxième trimestre de 2024 et a relevé ses prévisions de revenus pour l'année complète 2024. Les points clés comprennent :
- Revenus produits pour le deuxième trimestre 2024 : 45,1 millions de dollars, soit une augmentation de 16 % par rapport à l'année précédente
- Revenus produits pour le premier semestre 2024 : 83,4 millions de dollars, soit une augmentation de 20 % par rapport à l'année précédente
- Prévisions de revenus produits pour l'année complète 2024 relevées à 175-178 millions de dollars
- Perte nette GAAP pour le deuxième trimestre 2024 réduite à 5,8 millions de dollars
- EBITDA ajusté non-GAAP pour le deuxième trimestre 2024 : 0,8 million de dollars
- Flux de trésorerie d'exploitation positifs de 2,4 millions de dollars depuis le début de l'année
- Liquidités et investissements : 71,2 millions de dollars au 30 juin 2024
L'entreprise a signalé une forte croissance de son activité de plaquettes, en particulier en Amérique du Nord, et une adoption accélérée de l'INTERCEPT Fibrinogen Complex (IFC). Cerus reste déterminée à atteindre l'équilibre de l'EBITDA ajusté pour l'année 2024.
Cerus (Nasdaq: CERS) hat starke Finanzzahlen für das zweite Quartal 2024 veröffentlicht und die Umsatzprognose für das gesamte Jahr 2024 erhöht. Wichtige Highlights sind:
- Produktumsatz Q2 2024: 45,1 Millionen Dollar, ein Anstieg von 16% im Jahresvergleich
- Produktumsatz H1 2024: 83,4 Millionen Dollar, ein Anstieg von 20% im Jahresvergleich
- Umsatzprognose für das gesamte Jahr 2024 auf 175-178 Millionen Dollar erhöht
- GAAP-Nett Verlust im Q2 2024 auf 5,8 Millionen Dollar verringert
- Nicht-GAAP bereinigtes EBITDA im Q2 2024: 0,8 Millionen Dollar
- Positive operative Cashflows von 2,4 Millionen Dollar seit Jahresbeginn
- Bargeld und Investitionen: 71,2 Millionen Dollar zum 30. Juni 2024
Das Unternehmen meldete ein starkes Wachstum seines Geschäfts mit Thrombozyten, insbesondere in Nordamerika, und eine beschleunigte Einführung des INTERCEPT Fibrinogen-Komplexes (IFC). Cerus bleibt engagiert, das bereinigte EBITDA für das gesamte Jahr 2024 auszugleichen.
- Q2 2024 product revenue increased 16% year-over-year to $45.1 million
- H1 2024 product revenue grew 20% to $83.4 million
- Full-year 2024 product revenue guidance raised to $175-178 million
- Q2 2024 non-GAAP adjusted EBITDA positive at $0.8 million
- Positive operating cash flows of $2.4 million year-to-date
- 100% adoption of INTERCEPT platelets by Canadian Blood Services
- IFC sales grew to $2.0 million in Q2 2024, up from $1.4 million in Q2 2023
- Operating expenses decreased 19% year-over-year in Q2 2024
- Q2 2024 GAAP net loss of $5.8 million
- Government contract revenue decreased 39% year-over-year in Q2 2024
- $65.0 million outstanding on term loan and $18.8 million drawn on revolving credit facility
Insights
Cerus 's Q2 2024 results demonstrate solid growth and improved financial performance. Product revenue increased by
Key financial highlights include:
- Narrowed GAAP net loss to
$5.8 million from$13.3 million in Q2 2023 - Generated positive non-GAAP adjusted EBITDA of
$0.8 million - Positive operating cash flows of
$0.4 million for the quarter - Cash and short-term investments of
$71.2 million as of June 30, 2024
The company's improved financial performance is reflected in its decision to raise full-year 2024 product revenue guidance to
While these results are encouraging, investors should note that Cerus still operates at a net loss. The company's ability to continue narrowing losses and achieve profitability will be important for long-term sustainability and shareholder value creation.
Cerus 's Q2 2024 results highlight significant progress in the adoption and recognition of its pathogen reduction technologies. The achievement of 100% adoption of INTERCEPT platelets by Canadian Blood Services is a major milestone, effectively securing the majority of the Canadian platelet market. This widespread adoption underscores the growing acceptance of pathogen inactivation as a critical safety measure in blood transfusion practices.
The company's INTERCEPT Fibrinogen Complex (IFC) is gaining traction, with recent publications and case studies demonstrating its benefits in early intervention for bleeding patients and improved operational efficiency for hospital transfusion services. This growing body of evidence could accelerate IFC adoption in clinical settings.
Cerus is also advancing efforts to expand U.S. manufacturing capacity for IFC, which could potentially lead to increased production and sales in the future. Additionally, the ongoing development of next-generation pathogen reduction technology for whole blood and a lyophilized IFC formulation demonstrates the company's commitment to innovation in blood safety.
While the completion of the U.S. Phase 3 ReCePI clinical trial for INTERCEPT Red Blood Cells (RBCs) led to a decrease in government contract revenue, it marks progress towards potential future commercialization of this product. The development of pathogen reduction technology for RBCs could significantly expand Cerus' addressable market, as RBCs are the most commonly transfused blood component.
These advancements position Cerus well in the evolving landscape of blood safety and transfusion medicine, potentially leading to further market penetration and revenue growth in the coming years.
First Half of 2024 Product Revenue Increased
Increasing Full-Year 2024 Product Revenue Guidance Range from
Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %):
Three Months Ended |
|
Six Months Ended |
|||||||||||||||||||||||
June 30, |
Change |
June 30, |
Change |
||||||||||||||||||||||
2024 |
2023 |
$ |
% |
2024 |
2023 |
$ |
% |
||||||||||||||||||
Product Revenue |
$ |
45,079 |
$ |
38,853 |
$ |
6,226 |
|
16 |
% |
$ |
83,444 |
$ |
69,827 |
$ |
13,617 |
|
20 |
% |
|||||||
Government Contract Revenue |
|
5,440 |
|
8,875 |
|
(3,435 |
) |
-39 |
% |
|
10,470 |
|
16,377 |
|
(5,907 |
) |
-36 |
% |
|||||||
Total Revenue |
$ |
50,519 |
$ |
47,728 |
$ |
2,791 |
|
6 |
% |
$ |
93,914 |
$ |
86,204 |
$ |
7,710 |
|
9 |
% |
Recent highlights include:
-
Advanced efforts to expand the
U.S. manufacturing capacity for INTERCEPT Fibrinogen Complex (IFC). -
Achievement of
100% adoption of INTERCEPT platelets by Canadian Blood Services, resulting in the pathogen inactivation of the majority of platelets inCanada . -
Narrowed GAAP net loss attributable to Cerus Corporation to
and generated non-GAAP adjusted EBITDA of$5.8 million for the second quarter.$0.8 million -
Generated positive operating cash flows for the second straight quarter of 2024 bringing year-to-date positive operating cash flows to
.$2.4 million -
Cash and cash equivalents and short-term investments were
at June 30, 2024.$71.2 million -
The Company is increasing its full-year 2024 annual product revenue guidance range from
to$172 -175 million which includes$175 -178 million for IFC.$8 -10 million - The Company continues to expect future improvements to GAAP net loss attributable to Cerus Corporation for the full-year 2024 and remains committed to adjusted EBITDA breakeven for the full-year 2024.
“We are very pleased to post another strong quarter to continue our growth trajectory in 2024. North American sales in our platelet business led the way, including both organic
“We are also extremely pleased with our execution to date on key financial measures that we discussed at the beginning of the year, namely adjusted EBITDA and operating cash flows,” continued Greenman. “We will continue our efforts to improve on these metrics during the back half of 2024, which is expected to help further strengthen our financial position.”
Revenue
Product revenue during the second quarter of 2024 was
Second-quarter 2024 government contract revenue was
Product Gross Profit & Margin
Product gross profit for the second quarter of 2024 was
Operating Expenses
Total operating expenses for the second quarter of 2024 were
R&D expenses for the second quarter of 2024 were
SG&A expenses narrowed for the second quarter of 2024 and totaled
Net Loss Attributable to Cerus Corporation
Net loss attributable to Cerus Corporation for the second quarter of 2024 was
Non-GAAP Adjusted EBITDA
Non-GAAP adjusted EBITDA for the second quarter of 2024 was
Balance Sheet & Cash Flows
At June 30, 2024, the Company had cash and cash equivalents and short-term investments of
As of June 30, 2024, the Company had
For the second quarter of 2024, the Company generated positive cash flows of
Increasing 2024 Product Revenue Guidance
Given the strong performance in the first half and continued growing conviction around IFC demand, the Company expects full-year 2024 product revenue will be in the range of
Quarterly Conference Call
The Company will host a conference call at 4:30 P.M. EDT this afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.
A replay will be available on Cerus’ website approximately three hours after the call through August 22, 2024.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Forward Looking Statements
Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ 2024 annual product revenue guidance and related expectation for product revenue growth for 2024; Cerus’ expectation for full-year 2024 non-GAAP adjusted EBITDA breakeven; Cerus’ expectations with respect to product revenue gross margin in 2024; Cerus’ expectation for the return to growth of its platelets and plasma business and increasing contribution from its INTERCEPT Fibrinogen Complex (IFC) business; Cerus’ ability to expand the
Use of Non-GAAP Financial Measures
We define adjusted EBITDA as net loss attributable to Cerus Corporation as reported on the consolidated statement of operations, as adjusted to exclude, as applicable for the reporting period(s) presented, (i) net loss attributable to noncontrolling interest, (ii) provision for income taxes, (iii) foreign exchange (loss)/gain, (iv) interest income (expense), (v) other income (expense), net (vi) depreciation and amortization, (vii) share-based compensation, (viii) goodwill and asset impairments, (ix) costs associated with our noncontrolling interest in our joint venture in
Investors should note that Cerus has not provided a reconciliation of anticipated non-GAAP adjusted EBITDA for the year ending December 31, 2024 to projected GAAP net loss attributable to Cerus Corporation for the year ending December 31, 2024 because certain items such as share-based compensation that are components of GAAP net loss attributable to Cerus Corporation cannot be reasonably projected due to the significant impact of changes in Cerus’ stock price and other factors. These components of GAAP net loss attributable to Cerus Corporation could significantly impact the reported GAAP net loss attributable to Cerus Corporation.
Supplemental Tables
|
Three Months Ended |
Six Months Ended |
|
June 30, |
June 30 |
|
2024 vs. 2023 |
2024 vs. 2023 |
Platelet Kit Growth |
|
|
|
|
|
International |
|
|
Worldwide |
|
|
|
|
|
Change in Calculated Number of Treatable Platelet Doses |
|
|
|
|
|
International |
|
|
Worldwide |
|
|
* Dose treatable calculation based on the number of kits sold and the product configuration (single, double, and triple dose kits)
CERUS CORPORATION REVENUE BY REGION (in thousands, except percentages) |
|||||||||||||||||||||||||
|
Three Months Ended |
|
|
|
|
|
Six Months Ended |
|
|
|
|
||||||||||||||
|
June 30, |
|
Change |
|
June 30, |
|
Change |
||||||||||||||||||
|
2024 |
|
2023 |
|
$ |
|
% |
|
2024 |
|
2023 |
|
$ |
|
% |
||||||||||
|
$ |
30,796 |
|
$ |
24,477 |
|
$ |
6,319 |
|
|
26 |
% |
|
$ |
56,269 |
|
$ |
41,094 |
|
$ |
15,175 |
|
|
37 |
% |
|
|
13,725 |
|
|
13,533 |
|
|
192 |
|
|
1 |
% |
|
|
26,439 |
|
|
27,561 |
|
|
(1,122 |
) |
|
-4 |
% |
Other |
|
558 |
|
|
843 |
|
|
(285 |
) |
|
-34 |
% |
|
|
736 |
|
|
1,172 |
|
|
(436 |
) |
|
-37 |
% |
Total product revenue |
$ |
45,079 |
|
$ |
38,853 |
|
$ |
6,226 |
|
|
16 |
% |
|
$ |
83,444 |
|
$ |
69,827 |
|
$ |
13,617 |
|
|
20 |
% |
CERUS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (in thousands, except per share data) |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30, |
June 30, |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
Product revenue |
$ |
45,079 |
|
$ |
38,853 |
|
$ |
83,444 |
|
$ |
69,827 |
|
||||
Cost of product revenue |
|
20,413 |
|
|
17,515 |
|
|
37,506 |
|
|
31,202 |
|
||||
Gross profit on product revenue |
|
24,666 |
|
|
21,338 |
|
|
45,938 |
|
|
38,625 |
|
||||
Government contract revenue |
|
5,440 |
|
|
8,875 |
|
|
10,470 |
|
|
16,377 |
|
||||
Operating expenses: |
||||||||||||||||
Research and development |
|
14,969 |
|
|
19,184 |
|
|
29,451 |
|
|
36,568 |
|
||||
Selling, general and administrative |
|
18,973 |
|
|
20,541 |
|
|
38,772 |
|
|
42,092 |
|
||||
Restructuring |
|
- |
|
|
2,128 |
|
|
- |
|
|
2,128 |
|
||||
Total operating expenses |
|
33,942 |
|
|
41,853 |
|
|
68,223 |
|
|
80,788 |
|
||||
Loss from operations |
|
(3,836 |
) |
|
(11,640 |
) |
|
(11,815 |
) |
|
(25,786 |
) |
||||
Total non-operating expense, net |
|
(1,995 |
) |
|
(1,593 |
) |
|
(3,632 |
) |
|
(3,011 |
) |
||||
Loss before income taxes |
|
(5,831 |
) |
|
(13,233 |
) |
|
(15,447 |
) |
|
(28,797 |
) |
||||
(Benefit from) provision for income taxes |
|
(56 |
) |
|
98 |
|
|
18 |
|
|
175 |
|
||||
Net loss |
|
(5,775 |
) |
|
(13,331 |
) |
|
(15,465 |
) |
|
(28,972 |
) |
||||
Net loss attributable to noncontrolling interest |
|
- |
|
|
(56 |
) |
|
(2 |
) |
|
(78 |
) |
||||
Net loss attributable to Cerus Corporation |
$ |
(5,775 |
) |
$ |
(13,275 |
) |
$ |
(15,463 |
) |
$ |
(28,894 |
) |
||||
Net loss per share attributable to Cerus Corporation: |
|
|||||||||||||||
Basic and diluted |
$ |
(0.03 |
) |
$ |
(0.07 |
) |
$ |
(0.08 |
) |
$ |
(0.16 |
) |
||||
Weighted average shares outstanding: |
||||||||||||||||
Basic and diluted |
|
184,982 |
|
|
180,611 |
|
|
183,536 |
|
|
179,449 |
|
CERUS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||
June 30, |
December 31, |
|||||
2024 |
2023 |
|||||
ASSETS |
(unaudited) |
|||||
Current assets: |
||||||
Cash and cash equivalents |
$ |
12,402 |
|
$ |
11,647 |
|
Short-term investments |
|
58,792 |
|
|
54,205 |
|
Accounts receivable, net |
|
23,740 |
|
|
35,500 |
|
Current inventories |
|
36,290 |
|
|
39,868 |
|
Prepaid and other current assets |
|
3,806 |
|
|
3,221 |
|
Total current assets |
|
135,030 |
|
144,441 |
||
Non-current assets: |
||||||
Property and equipment, net |
|
7,781 |
|
8,640 |
||
Operating lease right-of-use assets |
|
9,581 |
|
10,713 |
||
Goodwill |
|
1,316 |
|
1,316 |
||
Non-current inventories |
|
16,801 |
|
19,501 |
||
Other assets and restricted cash |
|
14,987 |
|
13,137 |
||
Total assets |
$ |
185,496 |
$ |
197,748 |
||
LIABILITIES AND STOCKHOLDERS' EQUITY |
||||||
Current liabilities: |
||||||
Accounts payable and accrued liabilities |
$ |
31,787 |
$ |
43,067 |
||
Debt – current |
|
18,782 |
|
20,000 |
||
Operating lease liabilities – current |
|
2,219 |
|
2,452 |
||
Deferred revenue – current |
|
1,096 |
|
2,002 |
||
Total current liabilities |
|
53,884 |
|
67,521 |
||
Non-current liabilities: |
||||||
Debt – non-current |
|
64,840 |
|
59,796 |
||
Operating lease liabilities – non-current |
|
12,851 |
|
13,751 |
||
Other non-current liabilities |
|
3,620 |
|
3,236 |
||
Total liabilities |
|
135,195 |
|
144,304 |
||
Stockholders' equity: |
|
49,509 |
|
52,650 |
||
Noncontrolling interest |
|
792 |
|
794 |
||
Total liabilities and stockholders' equity |
$ |
185,496 |
$ |
197,748 |
CERUS CORPORATION UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA (in thousands) |
||||||||||||||||
Three Months Ended |
Six Months Ended |
|||||||||||||||
June 30 |
June 30 |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
Net loss attributable to Cerus Corporation |
$ |
(5,775 |
) |
$ |
(13,275 |
) |
$ |
(15,463 |
) |
$ |
(28,894 |
) |
||||
Adjustments to net loss attributable to Cerus Corporation: |
||||||||||||||||
Net loss attributable to noncontrolling interest |
|
- |
|
|
(56 |
) |
|
(2 |
) |
|
(78 |
) |
||||
(Benefit from) provision for income taxes |
|
(56 |
) |
|
98 |
|
|
18 |
|
|
175 |
|
||||
Total non-operating expense, net (i) |
|
1,995 |
|
|
1,593 |
|
|
3,632 |
|
|
3,011 |
|
||||
Loss from operations |
|
(3,836 |
) |
|
(11,640 |
) |
|
(11,815 |
) |
|
(25,786 |
) |
||||
Adjustments to loss from operations: |
||||||||||||||||
Operating depreciation and amortization |
|
1,127 |
|
|
1,164 |
|
|
2,344 |
|
|
2,170 |
|
||||
Government contract revenue (ii) |
|
(5,440 |
) |
|
(8,875 |
) |
|
(10,470 |
) |
|
(16,377 |
) |
||||
Direct expenses attributable to government contracts (iii) |
|
3,250 |
|
|
6,633 |
|
|
6,475 |
|
|
11,809 |
|
||||
Share-based compensation (iv) |
|
5,678 |
|
|
5,720 |
|
|
11,533 |
|
|
11,389 |
|
||||
Costs attributable to noncontrolling interest (v) |
|
- |
|
|
130 |
|
|
3 |
|
|
173 |
|
||||
Restructuring (vi) |
|
- |
|
|
2,128 |
|
|
- |
|
|
2,128 |
|
||||
Non-GAAP adjusted EBITDA |
$ |
779 |
|
$ |
(4,740 |
) |
$ |
(1,930 |
) |
$ |
(14,494 |
) |
i. Includes interest income/expense and foreign exchange gains/losses. |
||
ii. Represents revenue related to the cost reimbursement provisions under our government contracts. |
||
iii. Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflect under government contract revenue in the condensed consolidated statement of operations. |
||
iv. Represents non-cash stock-based compensation. |
||
v. Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang ( |
||
vi. Represents costs associated with the Company’s restructuring plan implemented in June 2023. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801921878/en/
Jessica Hanover – Vice President, Corporate Affairs
Cerus Corporation
925-288-6137
Source: Cerus Corporation
FAQ
What was Cerus 's Q2 2024 product revenue?
Has Cerus (CERS) updated its 2024 revenue guidance?
What was Cerus 's (CERS) net loss for Q2 2024?